Anteris Technologies Global Corp. (AVR)
NASDAQ: AVR · Real-Time Price · USD
6.65
-0.12 (-1.77%)
At close: Oct 12, 2026, 4:00 PM EDT
6.65
0.00 (0.00%)
After-hours: Oct 12, 2026, 4:10 PM EDT
AVR Revenue
Anteris Technologies Global had revenue of $1.01M in the quarter ending June 30, 2026, with 63.27% growth. This brings the company's revenue in the last twelve months to $2.24M, down -9.56% year-over-year. In the year 2025, Anteris Technologies Global had annual revenue of $1.91M, down -29.23%. That makes Anteris Technologies Global the 42,122nd largest company in the world by revenue and 5,714th in the United States.
Revenue (ttm)
$2.24M
Revenue Growth
-9.56%
P/S Ratio
289.18
Revenue / Employee
$12,885
Employees
174
Market Cap
648.33M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.91M | -790.00K | -29.23% |
| Dec 31, 2024 | 2.70M | -32.00K | -1.17% |
| Dec 31, 2023 | 2.74M | -384.72K | -12.33% |
| Dec 31, 2022 | 3.12M | -2.55M | -44.93% |
| Dec 31, 2021 | 5.66M | 203.73K | 3.73% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| AdaptHealth | 3.36B |
| Varex Imaging | 865.00M |
| InMode | 374.63M |
| Tactile Systems Technology | 350.31M |
| OrthoPediatrics | 252.72M |
| SI-BONE | 213.60M |
| Cytek Biosciences | 206.71M |
| Pacific Biosciences of California | 159.27M |
AVR News
- 6 weeks ago - Anteris to Present at September Healthcare Investor Conferences - GlobeNewsWire
- 2 months ago - Anteris Technologies Announces Results for the Second Quarter of 2026 - GlobeNewsWire
- 4 months ago - Anteris Advances Global PARADIGM Expansion with French Regulatory Clearance - GlobeNewsWire
- 5 months ago - Anteris Appoints Susan Knight and Stephen Denaro to its Board of Directors - GlobeNewsWire
- 5 months ago - Anteris Announces Results for the First Quarter of 2026 - GlobeNewsWire
- 5 months ago - Anteris Technologies Announces First U.S. Patients Treated in Global Pivotal PARADIGM Trial - GlobeNewsWire
- 5 months ago - Anteris Technologies Secures CMS Reimbursement Supporting U.S. Site Activation for PARADIGM Trial - GlobeNewsWire
- 7 months ago - Anteris Reports 2025 Financial Results and Provides Corporate Update - GlobeNewsWire